GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® ...
Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S ...
Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction ...
Amgen announced the launch of its direct-to-patient program providing eligible patients discounted pricing for evolocumab, a ...
Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha. This follows landmark results demonstrating ...
Clinical Trials Arena on MSN
Long-term benefit of Amgen’s Repatha in reducing MACE shown in Phase III trial
The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary ...
Findings from the Phase III VESALIUS-CV study reinforce the cholesterol-lowering benefit of Repatha in high-risk patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback